You are here: Home » Current Affairs » News » Health
Business Standard

New 'wonder-drug' may prevent brain cells from dying

Researchers found two drugs that block a major pathway which leads to brain cell death in mice

Press Trust of India  |  London 

New 'wonder-drug' may prevent brain cells from dying

in the UK have discovered a drug that may safely help prevent neurodegenerative diseases such as Alzheimer's and Parkinson's.

Researchers found two that block a major pathway which leads to cell death in mice and prevent neurodegeneration.

The caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials, researchers at Medical Council's (MRC) Toxicology Unit in Leicester, UK said.

Misfolded proteins build up in the in several neurodegenerative diseases and are a major factor in dementias such as Alzheimer's and Parkinson's as well as prion diseases.

Previously, the team found that the accumulation of misfolded proteins in mice with prion disease over-activates a natural defence mechanism, 'switching off' the vital production of new proteins in cells.

They then found switching protein production back on with an experimental drug halted neurodegeneration. However, the drug tested was toxic to the pancreas and not suitable for testing in humans.

In the latest study, published in the journal Brain, the team tested 1,040 compounds, first in worms (C elegans) which have a functioning nervous system and are a good experimental model for screening to be used on the nervous system and then in mammalian cells.

The researchers identified two that restored protein production rates in mice - trazodone hydrochloride, a licensed antidepressant, and dibenzoylmethane, a compound being trialled as an anti-cancer drug.

Both prevented the emergence of signs of cell damage in most of the prion-diseased mice and restored memory in frontotemporal dementia (FTD) mice.

In both mouse models, the reduced shrinkage which is a feature of the neurodegenerative disease.

"We know that trazodone is safe to use in humans, so a clinical trial is now possible to test whether the protective effects of the drug we see on cells in mice with neurodegeneration also applies to people in the early stages of Alzheimer's disease and other dementias," said Professor Giovanna Mallucci, who led the team from the MRC.

"We could know in 2-3 years whether this approach can slow down disease progression, which would be a very exciting first step in treating these disorders," said Mallucci, now based at the University of Cambridge.

"Interestingly, Trazodone has been used to treat the symptoms of patients in later stages of dementia, so we know it is safe for this group.

"We now need to find out whether giving the drug to patients at an early stage could help arrest or slow down the disease through its effects on this pathway," Mallucci said.

RECOMMENDED FOR YOU

New 'wonder-drug' may prevent brain cells from dying

Researchers found two drugs that block a major pathway which leads to brain cell death in mice

Researchers found two drugs that block a major pathway which leads to brain cell death in mice
in the UK have discovered a drug that may safely help prevent neurodegenerative diseases such as Alzheimer's and Parkinson's.

Researchers found two that block a major pathway which leads to cell death in mice and prevent neurodegeneration.

The caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials, researchers at Medical Council's (MRC) Toxicology Unit in Leicester, UK said.

Misfolded proteins build up in the in several neurodegenerative diseases and are a major factor in dementias such as Alzheimer's and Parkinson's as well as prion diseases.

Previously, the team found that the accumulation of misfolded proteins in mice with prion disease over-activates a natural defence mechanism, 'switching off' the vital production of new proteins in cells.

They then found switching protein production back on with an experimental drug halted neurodegeneration. However, the drug tested was toxic to the pancreas and not suitable for testing in humans.

In the latest study, published in the journal Brain, the team tested 1,040 compounds, first in worms (C elegans) which have a functioning nervous system and are a good experimental model for screening to be used on the nervous system and then in mammalian cells.

The researchers identified two that restored protein production rates in mice - trazodone hydrochloride, a licensed antidepressant, and dibenzoylmethane, a compound being trialled as an anti-cancer drug.

Both prevented the emergence of signs of cell damage in most of the prion-diseased mice and restored memory in frontotemporal dementia (FTD) mice.

In both mouse models, the reduced shrinkage which is a feature of the neurodegenerative disease.

"We know that trazodone is safe to use in humans, so a clinical trial is now possible to test whether the protective effects of the drug we see on cells in mice with neurodegeneration also applies to people in the early stages of Alzheimer's disease and other dementias," said Professor Giovanna Mallucci, who led the team from the MRC.

"We could know in 2-3 years whether this approach can slow down disease progression, which would be a very exciting first step in treating these disorders," said Mallucci, now based at the University of Cambridge.

"Interestingly, Trazodone has been used to treat the symptoms of patients in later stages of dementia, so we know it is safe for this group.

"We now need to find out whether giving the drug to patients at an early stage could help arrest or slow down the disease through its effects on this pathway," Mallucci said.
image
Business Standard
177 22

New 'wonder-drug' may prevent brain cells from dying

Researchers found two drugs that block a major pathway which leads to brain cell death in mice

in the UK have discovered a drug that may safely help prevent neurodegenerative diseases such as Alzheimer's and Parkinson's.

Researchers found two that block a major pathway which leads to cell death in mice and prevent neurodegeneration.

The caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials, researchers at Medical Council's (MRC) Toxicology Unit in Leicester, UK said.

Misfolded proteins build up in the in several neurodegenerative diseases and are a major factor in dementias such as Alzheimer's and Parkinson's as well as prion diseases.

Previously, the team found that the accumulation of misfolded proteins in mice with prion disease over-activates a natural defence mechanism, 'switching off' the vital production of new proteins in cells.

They then found switching protein production back on with an experimental drug halted neurodegeneration. However, the drug tested was toxic to the pancreas and not suitable for testing in humans.

In the latest study, published in the journal Brain, the team tested 1,040 compounds, first in worms (C elegans) which have a functioning nervous system and are a good experimental model for screening to be used on the nervous system and then in mammalian cells.

The researchers identified two that restored protein production rates in mice - trazodone hydrochloride, a licensed antidepressant, and dibenzoylmethane, a compound being trialled as an anti-cancer drug.

Both prevented the emergence of signs of cell damage in most of the prion-diseased mice and restored memory in frontotemporal dementia (FTD) mice.

In both mouse models, the reduced shrinkage which is a feature of the neurodegenerative disease.

"We know that trazodone is safe to use in humans, so a clinical trial is now possible to test whether the protective effects of the drug we see on cells in mice with neurodegeneration also applies to people in the early stages of Alzheimer's disease and other dementias," said Professor Giovanna Mallucci, who led the team from the MRC.

"We could know in 2-3 years whether this approach can slow down disease progression, which would be a very exciting first step in treating these disorders," said Mallucci, now based at the University of Cambridge.

"Interestingly, Trazodone has been used to treat the symptoms of patients in later stages of dementia, so we know it is safe for this group.

"We now need to find out whether giving the drug to patients at an early stage could help arrest or slow down the disease through its effects on this pathway," Mallucci said.

image
Business Standard
177 22